Depression in somatic diseases. In which groups of patients should be applied tianeptine? Review article
Article Sidebar
Main Article Content
Abstract
Depression is a serious disease carrying to significant consequences, not only health, but also social. It is estimated as one of the main causes of hospitalization among both women and men over 50. Annually about 100 million people around the world show the symptoms of depression. The most visible symptoms of this disease are related to the emotional sphere, but equally strongly depression affects the cognitive functioning of patients. A person with depression has great difficulty in performing professional duties and housework. Severe episodes, called major depression, almost completely prevent their execution, with the exception of minor acts of self-service. Depression increases the risk of heart failure, especially of patients with coronary artery disease, and is associated with poor quality of life, the use of multiple medications, a higher incidence of adverse events and hospitalization and increased mortality risk. It is estimated that early diagnosed depression is a treatable disease in about 80%, but there is a high risk of recurrence of symptoms. Preventing recurrence in depression has become one of the most important tasks of healing and in the first period is primarily effective treatment of this episode. Preventing recurrence in depression has become one of the most important tasks of healing the disease. Tianeptine appears to be the drug particularly useful in the treatment of depression in patients with somatic diseases, not only because the effectiveness of antidepressant and anxiolytic was confirmed by research, but also good tolerability, safety and low risk of drug interactions.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Kessler R.C., Zhao S., Blazer D.G., Swartz M.: Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey. J. Affect. Disord. 1997; 45(1-2): 19-30.
3. Blazer D.G., Kessler R.C., McGonagle K.A., Swartz M.S.: The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am. J. Psychiatry 1994; 151(7): 979-986.
4. Tylee A.: Depression in Europe: experience from the DEPRES II survey. Depression Research in European Society. Eur. Neuropsychopharmacol. 2000; Supl. 4: S445-448.
5. Rustad J.K., Stern T.A., Hebert K.A., Musselman D.L.: Diagnosis and treatment of depression in patients with congestive heart failure: a review of the literature. Prim. Care Companion. CNS Disord. 2013; 15(4) [pii: PCC.13r01511; doi: 10.4088/PCC.13r01511].
6. Dróżdż W., Wojnar M., Araszkiewicz A. et al.: Badanie rozpowszechnienia zaburzeń depresyjnych u pacjentów podstawowej opieki zdrowotnej w Polsce. Wiad. Lek. 2007; 60: 3-4.
7. Sartorius N.: Promocja zdrowia – depresja. WPA Bulletin on Depression 2002; 5(24).
8. Whooley M.A., Kiefe C.I., Chesney M.A. et al.: Depressive symptoms, unemployment, and loss of income: The CARDIA Study. Arch. Intern. Med. 2002; 162(22): 2614-2620.
9. Wojnar M., Czernikiewicz A.: Wartość kliniczna Skali Depresji Raskina w praktyce lekarza pierwszego kontaktu. Psych. Prakt. Ogólnolek. 2004; 4(1).
10. ICD-10. Międzynarodowa Statystyczna Klasyfikacja Chorób i Problemów Zdrowotnych. Rewizja dziesiąta. Rozdział V: Zaburzenia psychiczne i zaburzenia zachowania (F00-F99). Vesalius, Kraków 1994.
11. Kasper S., McEwen B.S.: Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs 2008; 22(1): 15-26.
12. Patejuk-Mazurek I.: Tianeptyna – efekty neuroplastyczne a zastosowanie w specyficznych grupach pacjentów. Opisy przypadków. Psychiatria 2014; 11(4): 211-214.
13. Jeon H.J., Woo J.M., Lee S.H. et al.: Improvement in subjective and objective neurocognitive functions in patients with major depressive disorder: a 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study. J. Clin. Psychopharmacol. 2014; 34(2): 218-225.
14. Dufouil C., Fuhrer R., Dartigues J., Alpérovitch A.: Longitudinal analysis of the association between depressive symptomatology and cognitive deterioration. Am. J. Epidemiol. 1996; 144(7): 634-641.
15. Wilson R., Mendes de Leon C., Bennett D. et. al.: Depressive symptoms and cognitive decline in a community population of older persons. J. Neurol. Neurosurg. Psychiatry 2004; 75: 126-129.
16. Chapuy P., Cuny G., Delomier Y. et al.: Depression in elderly patients. Value of tianeptine in 140 patients treated for 1 year [in French]. Presse Med. 1991; 20(37): 1844-1852.
17. Dovzhenko T.V., Vasiuk I.A., Semiglazova M.V. et al.: The clinical picture and treatment of depression spectrum disorders in patients with cardiovascular disease. Ter. Arkh. 2009; 81(12): 30-34.
18. Vasiuk I.A., Lebedev A.V., Dovzhenko T.V., Semiglazova M.V.: Affective disorders in acute myocardial infarction and possibilities of their correction with tianeptin. Ter. Arkh. 2010; 82(10): 28-33.
19. Lasnier C., Marey C., Lapeyre G. et al.: Cardiovascular tolerance to tianeptine. Presse Med. 1991; 20(37): 1858-1863.
20. O’Neil A., Taylor B., Hare D.L. et al.; on behalf of the MoodCare Investigator Team: Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Eur. J. Prev. Cardiol. 2014 [pii: 2047487314547655].
21. Bosak M., Dudek D., Siwek M.: Depresja u chorych z padaczką. Psychiatr. Pol. 2012; 46(5): 891-902.
22. Moon J., Jung K.H., Shin J.W. et al.: Safety of tianeptine use in patients with epilepsy. Epilepsy Behav. 2014; 34: 116-119.
23. Bartnik W., Chojnacki J., Paradowski L. et al.: Rekomendacje diagnostyczno-terapeutyczne w zespole jelita nadwrażliwego. Gastroenterol. Klin. 2009; 1(1): 9-17.
24. Nehring P., Mrozikiewicz-Rakowska B., Krasnodębski P., Karnafel W.: Zespół jelita drażliwego – nowe spojrzenie na etiopatogenezę. Prz. Gastroenterol. 2011; 6(1): 17-22.
25. Sohn W., Lee O.Y., Kwon J.G. et al.: Tianeptine vs amitriptyline for the treatment of irritable bowel syndrome with diarrhea: a multicenter, open-label, non-inferiority, randomized controlled study. Neurogastroenterol Motil. 2012; 24(9): 860-e398.
26. Radziwiłłowicz P., Gil K.: Zespół jelita drażliwego (zjd) okiem psychiatry. Psychiatr. Pol. 2007; 41(1): 87-97.
27. Krogulski S., Lipińska-Szałek A.: Depresje menopauzalne – nietypowy obraz kliniczny, leczenie. Prz. Menopauzal. 2004; 3: 31-38.
28. Jałocha W., Walecka-Kapica E., Tomaszewska-Warda K. et al.: The effect of fluoxetine and tianeptine on emotional and eating disorders in postmenopausal women. Pol. Merk. Lek. 2014; 37(217): 35-38.
29. Jałocha W., Walecka-Kapica E., Tomaszewska-Warda K. et al.: Depresja i leczenie tianeptyną. Neuropsychiatria. Przegląd Kliniczny 2012; 4(2): 69-75.
30. Kasper S., Olié J.P.: A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. Eur. Psychiatry 2002; 17(3): 331-340.